Literature DB >> 19557321

[Acromegaly-associated lesions of the nasal mucosa. Case report].

J Flitsch1, D K Lüdecke, W Saeger, J A Veit, F U Metternich.   

Abstract

Acromegaly is a rare disease caused by a growth-hormone-secreting pituitary adenoma. Symptoms include enlargement of the hands, feet, and jaw with growing dental interspaces, as well as hypertrophy of the tongue and nasal and sinusoidal mucosa. The two latter symptoms are mostly responsible for the accompanying obstructive sleep apnea syndrome. Besides these "cosmetic" symptoms, the disease is associated with hypertension and diabetes mellitus, as well as with an increased risk for adenomas and carcinomas of the colon. The average time span from first symptom to diagnosis is well over 6 years; a single determination of insulin-like growth factor 1 in serum can confirm the disease. The treatment of choice remains surgical resection of the adenoma in suitable patients, whereas in extensive disease with invasion of surrounding tissue, drug therapy and/or radiotherapy may be necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19557321     DOI: 10.1007/s00106-009-1951-y

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  8 in total

Review 1.  Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.

Authors:  Dieter K Ludecke; Takumi Abe
Journal:  Neuroendocrinology       Date:  2006       Impact factor: 4.914

2.  Acromegaly and the risk of cancer.

Authors:  Bogdan Marek; Dariusz Kajdaniuk; Beata Kos-Kudl&z shtsls;a; Zofia Ostrowska; Danuta Niedziol&z shtsls;ka; Ewa Janczewska-Kazek
Journal:  Pathophysiology       Date:  2001-12

3.  Pressure-irrigation-suction system. Technical note.

Authors:  D K Lüdecke; W Treige
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

4.  Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.

Authors:  T Abe; D K Lüdecke
Journal:  Eur J Endocrinol       Date:  2001-08       Impact factor: 6.664

5.  Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process.

Authors:  J Flitsch; S Spitzner; D K Lüdecke
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

6.  Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.

Authors:  V J Moyes; K A Metcalfe; W M Drake
Journal:  Eur J Endocrinol       Date:  2008-08-15       Impact factor: 6.664

7.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

8.  Management of inverted papilloma of the nose and paranasal sinuses.

Authors:  E N Myers; V L Schramm; E L Barnes
Journal:  Laryngoscope       Date:  1981-12       Impact factor: 3.325

  8 in total
  1 in total

1.  The problem of unrecognized acromegaly: surgeries patients undergo prior to diagnosis of acromegaly.

Authors:  F E Keskin; D O Yetkin; H M Ozkaya; O Haliloglu; S Sadri; N Gazioglu; N Tanrıover; H Ak; E Hatipoglu; P Kadıoglu
Journal:  J Endocrinol Invest       Date:  2015-02-26       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.